ClinicalTrials.gg
RecruitingNCT07436741Updated Jul 10, 2026

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

A Phase 3 interventional study of surufatinib + gemcitabine + nab-paclitaxel and gemcitabine + nab-paclitaxel in Pancreatic Cancer, Adult, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer

02

Conditions studied

  • Pancreatic Cancer, Adult
03

In context

Pancreatic cancer, adult

25 studies on the registry are indexed under Pancreatic cancer, adult; 18 are open to participants now.

This study's planned enrollment of 106 is above the median of 90 across 17 interventional studies indexed under Pancreatic cancer, adult.

Browse Pancreatic cancer, adult studies →

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 499 studies on the registry; 298 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;
  • 18-75 years old (including 18 and 75 years old);
  • No BRCA1/2 or PALB2 mutation;
  • No previous pancreatic cancer resection, systemic therapy, or local radiation therapy;
  • Eastern Cooperation Oncology Group () performance status of 0-1;
  • ≥ 6 months;
  • At least one according to version 1.1;
  • Adequate organ and bone marrow functions;
  • Women of childbearing age need to take effective measures.

Exclusion criteria

Exclusion Criteria:

  • With distant ;
  • Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;
  • Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);
  • Allergic to the study drug or any of its adjuvants;
  • Researchers judged electrolyte abnormalities;
  • History of serious cardiovascular and cerebrovascular diseases;
  • With active ulcer, intestinal perforation and intestinal obstruction;
  • Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture according to the judgment of the investigator);
  • Clinically significant electrolyte abnormalities judged by researchers;
  • With active bleeding or obvious evidence of bleeding tendency;
  • Hypertension that cannot be controlled by drugs: systolic blood pressure ≥ 150 mmHg and / or diastolic blood pressure ≥ 100 mmHg;
  • Women who are pregnant or lactating;
  • Urinary protein ≥ ++, or the 24-hour urine protein quantification is greater than 1.0g;
  • Concurrent tumors within 5 years (except treated cervical carcinoma in situ, basal cell carcinoma);
  • Any disease or state that affects the absorption of drugs, or the subject cannot take oral drugs;
  • Known (HIV) infection;
  • History of clinically significant hepatic disease, including, but not limited to, known virus (HBV) infection with HBV DNA positive (copies ≥1×10\^4/ml or >2000 IU/ml); known virus infection with HCV RNA positive (copies ≥1×10\^3/m); hepatitis and cirrhosis;
  • Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    SUR+AG

    Surufatinib Plus Gemcitabine and Nab-paclitaxel

    Drug: surufatinib + gemcitabine + nab-paclitaxel

  • Active comparator
    AG

    Gemcitabine Plus Nab-paclitaxel

    Drug: gemcitabine + nab-paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Surgical complete resection rate (R0)

    This is a complete macroscopic resection of the gross tumor with negative surgical margins

    Time frame: about 1 year

Secondary outcomes

  1. Event-free survival (EFS)

    The time from randomization to the first event of disease progression that precluded surgery, local or distant recurrence, or death from any cause

    Time frame: about 2 years

  2. Objective Response Rate (ORR)

    ORR= Complete response rate + partial response rate

    Time frame: about 1 year

  3. Disease Control Rate (DCR)

    DCR= Complete response rate + partial response rate + disease stable rate

    Time frame: about 1 year

  4. Downstaging Rate

    To determine the rate of downstaging after preoperative therapy

    Time frame: about 1 year

  5. Pathological complete response (pCR) rate

    pCR is defined as the absence of residual tumor cells in the pathological examination after resection

    Time frame: about 1 year

  6. Overall survival (OS)

    Time from randomization to death

    Time frame: about 5 years

  7. Adverse events (AEs)

    treatment-related adverse events and serious adverse events as assessed by CTCAE v6.0

    Time frame: about 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Feb 27, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Mar 2030
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436741
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 3, 2026
Primary completion
Sep 2028 (estimated)
Completion
Mar 2030 (estimated)
Last update
Jul 10, 2026

Study contacts

Jihui Hao, M.D.
Contact
ec_tjcih@126.com
022-23524155
Song Gao, M.D.
Contact
foxgao2004@163.com
Jihui Hao, M.D.
principal investigator · Tianjin Medical University Cancer Institute and Hospital
Song Gao, M.D.
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Surufatinib · Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion